Skip to main content
ARVN
NASDAQ Life Sciences

Arvinas Secures $35M Upfront Payment as VEPPANU Licensing Deal with Rigel Becomes Effective

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$7.42
Mkt Cap
$478.747M
52W Low
$6.055
52W High
$14.51
52W Position info
23% above low
Off High info
49% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

ARVN sits 23% above its 52-week low of $6.055.

Summary

Arvinas announced its VEPPANU licensing deal with Rigel Pharmaceuticals is now effective, bringing in $35 million upfront and securing future milestone payments and royalties.


Key Events · M&A and Partnerships · ARVN

  • Licensing Agreement Finalized

    The global licensing agreement with Rigel Pharmaceuticals for VEPPANU is now effective following Hart-Scott-Rodino antitrust clearance.

  • Immediate Cash Infusion

    Arvinas received $35.0 million as its share of the $70.0 million upfront payment from Rigel.

  • Additional Near-Term Payment

    An additional $7.5 million is expected upon successful completion of development and manufacturing transition activities.

  • Future Milestones and Royalties

    The company is eligible for up to $160.0 million in future development, regulatory, and commercial milestone payments, plus tiered royalties on worldwide net sales.


Analysis · ARVN · Life Sciences

This filing confirms the finalization of the global licensing agreement for VEPPANU with Rigel Pharmaceuticals, following HSR antitrust clearance. Arvinas immediately receives $35 million as its share of the upfront payment, with an additional $7.5 million expected upon completion of transition activities. This significant cash infusion, totaling $42.5 million in the near term, substantially strengthens the company's financial position and provides capital for ongoing operations and pipeline development. The deal also includes potential future milestone payments up to $160 million and tiered royalties, establishing a long-term revenue stream for its FDA-approved drug.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARVN was trading at $7.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $478.7M. The 52-week trading range was $6.06 to $14.51. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARVN - Latest Insights

ARVN
Nov 03, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.09
Real-time Price: $6.77 info
Change: -$0.325 (-5%) info
Market Cap: $443.006M info
ARVN
Nov 03, 2026, 8:09 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.06
Real-time Price: $6.77 info
Change: -$0.295 (-4%) info
Market Cap: $443.006M info
ARVN
Nov 03, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $6.77 info
Change: -$0.755 (-10%) info
Market Cap: $443.006M info
ARVN
Oct 07, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $6.77 info
Change: -$0.755 (-10%) info
Market Cap: $443.006M info
ARVN
Sep 28, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.60
Real-time Price: $6.77 info
Change: -$0.835 (-11%) info
Market Cap: $443.006M info